{
  "ukCompanyRegNum": "04615761",
  "projects": [
    {
      "outputs": [],
      "start_raw": "2017-04-01",
      "year": 2018.0,
      "@type": "Project",
      "inputs": [
        {
          "@type": "Money",
          "name": "annualCosts",
          "raw": "22754000",
          "currency": "GBP",
          "value100p": 2.2754E11,
          "value": 2.2754E7
        },
        {
          "@type": "Money",
          "name": "fundraisingCosts",
          "currency": "GBP"
        },
        {
          "@type": "Money",
          "name": "tradingCosts",
          "raw": "0",
          "currency": "GBP",
          "value100p": 0.0,
          "value": 0.0
        },
        {
          "@type": "Money",
          "name": "incomeFromBeneficiaries",
          "raw": "0",
          "currency": "GBP",
          "value100p": 0.0,
          "value": 0.0
        }
      ],
      "name": "overall",
      "start": "2017-04-01",
      "end": "2018-03-31",
      "end_raw": "2018-03-31"
    },
    {
      "outputs": [],
      "data-src": [
        {
          "@type": "Citation",
          "url": "https://www.royalmarsden.org/sites/default/files/2019-10/RMCC_Annual-Report-and-Accounts-2018_19_Web.pdf"
        }
      ],
      "start_raw": "2018-04-01",
      "year": 2019.0,
      "@type": "Project",
      "inputs": [
        {
          "@type": "Money",
          "name": "annualCosts",
          "raw": "31413000",
          "currency": "GBP",
          "value100p": 3.1413E11,
          "value": 3.1413E7
        },
        {
          "@type": "Money",
          "name": "fundraisingCosts",
          "currency": "GBP"
        },
        {
          "@type": "Money",
          "name": "tradingCosts",
          "raw": "81000",
          "currency": "GBP",
          "value100p": 8.1E8,
          "value": 81000.0
        },
        {
          "@type": "Money",
          "name": "incomeFromBeneficiaries",
          "raw": "0",
          "currency": "GBP",
          "value100p": 0.0,
          "value": 0.0
        }
      ],
      "name": "overall",
      "start": "2018-04-01",
      "end": "2019-03-31",
      "reserves": {
        "@type": "Money",
        "raw": "19620000",
        "currency": "GBP",
        "value100p": 1.962E11,
        "value": 1.962E7
      },
      "end_raw": "2019-03-31"
    },
    {
      "outputs": [],
      "data-src": [
        {
          "@type": "Citation",
          "url": "https://www.royalmarsden.org/sites/default/files/2019-10/RMCC_Impact-Report-2018_19_Web.pdf"
        }
      ],
      "start_raw": "2018-04-01",
      "year": 2019.0,
      "@type": "Project",
      "inputs": [
        {
          "@type": "Money",
          "name": "annualCosts",
          "currency": "GBP"
        },
        {
          "@type": "Money",
          "name": "fundraisingCosts",
          "currency": "GBP"
        },
        {
          "@type": "Money",
          "name": "tradingCosts",
          "currency": "GBP"
        },
        {
          "@type": "Money",
          "name": "incomeFromBeneficiaries",
          "currency": "GBP"
        },
        {
          "@type": "Money",
          "name": "projectCosts",
          "raw": "3000000",
          "currency": "GBP",
          "value100p": 3.0E10,
          "value": 3000000.0
        }
      ],
      "name": "Research",
      "start": "2018-04-01",
      "end": "2019-03-31",
      "end_raw": "2019-03-31"
    },
    {
      "outputs": [],
      "data-src": [
        {
          "@type": "Citation",
          "url": "https://www.royalmarsden.org/sites/default/files/2019-10/RMCC_Impact-Report-2018_19_Web.pdf"
        }
      ],
      "start_raw": "2018-04-01",
      "year": 2019.0,
      "@type": "Project",
      "inputs": [
        {
          "@type": "Money",
          "name": "annualCosts",
          "currency": "GBP"
        },
        {
          "@type": "Money",
          "name": "fundraisingCosts",
          "currency": "GBP"
        },
        {
          "@type": "Money",
          "name": "tradingCosts",
          "currency": "GBP"
        },
        {
          "@type": "Money",
          "name": "incomeFromBeneficiaries",
          "currency": "GBP"
        },
        {
          "@type": "Money",
          "name": "projectCosts",
          "raw": "7100000",
          "currency": "GBP",
          "value100p": 7.1E10,
          "value": 7100000.0
        }
      ],
      "name": "Equipment",
      "start": "2018-04-01",
      "end": "2019-03-31",
      "end_raw": "2019-03-31"
    },
    {
      "outputs": [],
      "data-src": [
        {
          "@type": "Citation",
          "url": "https://www.royalmarsden.org/sites/default/files/2019-10/RMCC_Impact-Report-2018_19_Web.pdf"
        }
      ],
      "start_raw": "2018-04-01",
      "year": 2019.0,
      "@type": "Project",
      "inputs": [
        {
          "@type": "Money",
          "name": "annualCosts",
          "currency": "GBP"
        },
        {
          "@type": "Money",
          "name": "fundraisingCosts",
          "currency": "GBP"
        },
        {
          "@type": "Money",
          "name": "tradingCosts",
          "currency": "GBP"
        },
        {
          "@type": "Money",
          "name": "incomeFromBeneficiaries",
          "currency": "GBP"
        },
        {
          "@type": "Money",
          "name": "projectCosts",
          "raw": "8300000",
          "currency": "GBP",
          "value100p": 8.3E10,
          "value": 8300000.0
        }
      ],
      "name": "Treatment and care",
      "start": "2018-04-01",
      "end": "2019-03-31",
      "end_raw": "2019-03-31"
    },
    {
      "outputs": [],
      "data-src": [
        {
          "@type": "Citation",
          "url": "https://www.royalmarsden.org/sites/default/files/2019-10/RMCC_Impact-Report-2018_19_Web.pdf"
        }
      ],
      "start_raw": "2017-04-01",
      "year": 2019.0,
      "@type": "Project",
      "inputs": [
        {
          "@type": "Money",
          "name": "annualCosts",
          "currency": "GBP"
        },
        {
          "@type": "Money",
          "name": "fundraisingCosts",
          "currency": "GBP"
        },
        {
          "@type": "Money",
          "name": "tradingCosts",
          "currency": "GBP"
        },
        {
          "@type": "Money",
          "name": "incomeFromBeneficiaries",
          "currency": "GBP"
        },
        {
          "@type": "Money",
          "name": "projectCosts",
          "raw": "8300000",
          "currency": "GBP",
          "value100p": 8.3E10,
          "value": 8300000.0
        }
      ],
      "name": "Patient environments",
      "start": "2017-04-01",
      "end": "2019-03-31",
      "end_raw": "2019-03-31"
    },
    {
      "outputs": [],
      "data-src": [
        {
          "@type": "Citation",
          "url": "https://register-of-charities.charitycommission.gov.uk/charity-search/-/charity-details/3996971/accounts-and-annual-returns"
        }
      ],
      "year": 2021.0,
      "@type": "Project",
      "inputs": [
        {
          "@type": "Money",
          "name": "annualCosts",
          "raw": "48472000",
          "currency": "GBP",
          "value100p": 4.8472E11,
          "value": 4.8472E7
        },
        {
          "@type": "Money",
          "name": "tradingCosts",
          "raw": "49000",
          "currency": "GBP",
          "value100p": 4.9E8,
          "value": 49000.0
        },
        {
          "@type": "Money",
          "name": "incomeFromBeneficiaries",
          "currency": "GBP"
        }
      ],
      "meta": {
        "inputs_meta": {
          "notes": "Obviously some of the donations will be coming from people who were treated at the hospital, or had loved ones treated at the hospital, but it doesn\u0027t seem that this should be included as income from beneficiaries.\n"
        }
      },
      "name": "overall",
      "reserves": {
        "@type": "Money",
        "name": "",
        "raw": "18395000",
        "currency": "",
        "value100p": 1.8395E11,
        "value": 1.8395E7
      }
    },
    {
      "outputs": [],
      "year": 2021.0,
      "@type": "Project",
      "inputs": [
        {
          "@type": "Money",
          "name": "annualCosts",
          "currency": "GBP"
        },
        {
          "@type": "Money",
          "name": "tradingCosts",
          "currency": "GBP"
        },
        {
          "@type": "Money",
          "name": "incomeFromBeneficiaries",
          "currency": "GBP"
        },
        {
          "@type": "Money",
          "name": "projectCosts",
          "raw": "25000000",
          "currency": "GBP",
          "value100p": 2.5E11,
          "value": 2.5E7
        }
      ],
      "meta": {
        "inputs_meta": {
          "notes": ""
        }
      },
      "name": "Oak Cancer Centre",
      "isRep": true
    },
    {
      "outputs": [],
      "year": 2021.0,
      "@type": "Project",
      "inputs": [
        {
          "@type": "Money",
          "name": "annualCosts",
          "currency": "GBP"
        },
        {
          "@type": "Money",
          "name": "tradingCosts",
          "currency": "GBP"
        },
        {
          "@type": "Money",
          "name": "incomeFromBeneficiaries",
          "currency": "GBP"
        },
        {
          "@type": "Money",
          "name": "projectCosts",
          "raw": "3299000",
          "currency": "GBP",
          "value100p": 3.299E10,
          "value": 3299000.0
        }
      ],
      "name": "Research"
    },
    {
      "outputs": [],
      "year": 2021.0,
      "@type": "Project",
      "inputs": [
        {
          "@type": "Money",
          "name": "annualCosts",
          "currency": "GBP"
        },
        {
          "@type": "Money",
          "name": "tradingCosts",
          "currency": "GBP"
        },
        {
          "@type": "Money",
          "name": "incomeFromBeneficiaries",
          "currency": "GBP"
        },
        {
          "@type": "Money",
          "name": "projectCosts",
          "raw": "4358000",
          "currency": "GBP",
          "value100p": 4.358E10,
          "value": 4358000.0
        }
      ],
      "name": "Equipment"
    },
    {
      "outputs": [],
      "year": 2021.0,
      "@type": "Project",
      "inputs": [
        {
          "@type": "Money",
          "name": "annualCosts",
          "currency": "GBP"
        },
        {
          "@type": "Money",
          "name": "tradingCosts",
          "currency": "GBP"
        },
        {
          "@type": "Money",
          "name": "incomeFromBeneficiaries",
          "currency": "GBP"
        },
        {
          "@type": "Money",
          "name": "projectCosts",
          "raw": "9614000",
          "currency": "GBP",
          "value100p": 9.614E10,
          "value": 9614000.0
        }
      ],
      "name": "Treatment and Care"
    },
    {
      "outputs": [],
      "year": 2021.0,
      "@type": "Project",
      "inputs": [
        {
          "@type": "Money",
          "name": "annualCosts",
          "currency": "GBP"
        },
        {
          "@type": "Money",
          "name": "tradingCosts",
          "currency": "GBP"
        },
        {
          "@type": "Money",
          "name": "incomeFromBeneficiaries",
          "currency": "GBP"
        },
        {
          "@type": "Money",
          "name": "projectCosts",
          "raw": "475000",
          "currency": "GBP",
          "value100p": 4.75E9,
          "value": 475000.0
        }
      ],
      "name": "Patient and Staff Amenities"
    }
  ],
  "@type": "NGO",
  "displayName": "The Royal Marsden Cancer Charity",
  "description": "The Royal Marsden Cancer Charity raises funds, in addition to those provided by the NHS, for The Royal Marsden Cancer Centre, which conducts cancer research and offers patients personally tailored treatments. The charity also helps fund the purchase of and the upgrading of patient environments.",
  "recommendation": "**Summary**\n\n**The Royal Marsden Cancer Charity is rated as Not Recommended (Tentative) on the SoGive ratings scale.**\n\n- The Royal Marsden Cancer Charity provides funds solely to the Royal Marsden Cancer Centre to augment its NHS funding.\n- Given its membership in NHS Charities Together, at the outset we can expect that the Royal Marsden Cancer Charity will underperform the NHS’s own cost-effectiveness standards.\n- The Charity’s annual report and impact report do not provide information to the contrary, leading us to assume that they underperform the NHS’s own cost-effectiveness standards, though more information is needed to make certain of this.\n- Given that the NHS’s cost-effectiveness standards are far below SoGive’s, it is likely that a donation to the Royal Marsden Cancer Charity will have less of a positive impact than a donation to a SoGive Gold-rated charity.\n\n**The SoGive approach**\n\nUnder the SoGive [two question method](https://thinkingaboutcharity.blogspot.com/2021/04/sogives-analysis-methodology.html?view\u003dsidebar), we first consider two questions:\n- How much does it cost for the charity to do something?\n- What benefit is provided (or what does the beneficiary get for the donor\u0027s money)?\n\nWe explore these questions in the next section. From this information, we then estimate the charity’s cost-effectiveness. We then compare this with the SoGive Gold Standard benchmarks, which gives us an indication of how the charity compares to the most cost-effective charities we know about.\n\n**More about what Royal Marsden Cancer Charity does - how they spend your donations**\n\nThe Royal Marsden Cancer Charity (The Charity) provides additional funding to the Royal Marsden Cancer Centre (The Centre), on top of what the Centre receives in NHS funding. In its annual report for the 2020/2021 financial year, the Charity reported roughly £43 million contributed to the Centre, while in the same year the Centre’s total expenditure was just above £482 million.\n\nThe Charity donates funds for several purposes, all at the Royal Marsden Cancer Centre. It purchases new equipment: in 2021 it purchased a CyberKnife radiotherapy machine at a cost of £1.4 million, which will allow for greater accuracy and potency in radiation treatment; it offers grants for projects in education and patient care at the Centre; it helps fund capital projects for the Centre; it funds cancer research at the Centre. \n\nThis year, The Charity donated £25 million specifically for the Oak Cancer Centre; this amount comes from a single donation by the Oak Foundation. The Charity has raised £65 million of its £70 million goal for the project, and this, along with the effects of the pandemic, mean that its finances will be somewhat different next year, but year-to-year variation in its total fundraising will not be particularly important for our cost-effectiveness calculations below. The Charity spent an additional £4.3 million on equipment, £7.8 million in other grants (\"Innovation and Education,\" \"Sutton Hospital Enabling Works\"), £1.8 million for a Covid Emergency Fund, and £3.3 million on research. \n\n**Cost-effectiveness analysis - how does the RMCC compare to the most cost-effective charities?**\n\nAfter a review of the work of The Royal Marsden Cancer Charity under the two-question method, the next step in the SoGive process involves comparing this charity to SoGive’s Gold Standard for charity cost-effectiveness. To receive a firm Gold ranking, a charity has to achieve a high impact per pound donated (such as averting one year of severe depression for £200, or saving a life for £5,000), and also provide robust evidence on the effectiveness of their work. The process used to determine the SoGive Gold Standard benchmarks is set out [here](https://thinkingaboutcharity.blogspot.com/2021/04/sogives-gold-standard-benchmarks.html?view\u003dsidebar), and for more information on how we define our Gold, Silver, and Bronze rankings, click [here](https://thinkingaboutcharity.blogspot.com/2021/04/sogive-assigns-ratings-to-charities-or.html)\n\nUnfortunately, the Charity’s annual report does not provide numbers on the individuals impacted by their efforts, nor does it make an effort to quantify benefits such individuals might receive. Still, we can come up with a rough estimate of the Charity’s impact given that all its funds are directed to the Royal Marsden Cancer Centre.\n\nThe Centre, as mentioned above, had an expenditure of £482 million in 2021, and treated  54,000 individuals. This gives us an initial figure of £8,900 per patient treated. Obviously not every single patient treated has had their life saved, but even if that were the case, the Center, if it were being evaluated, would fail to meet SoGive’s Gold Standard, which is £5,000 per life saved. Since the Charity solely funds the Centre, it seems fair to assume that it likewise does not meet the Gold Standard.\n\nThere is another reason to doubt the Charity’s cost-effectiveness relative to the Gold Standard. Like other charities belonging to NHS Charities Together, the Royal Marsden Cancer Charity does not typically encroach on activities which fall under the remit of the NHS. [Absent specific defeators] (https://www.nice.org.uk/process/pmg6/chapter/assessing-cost-effectiveness), the NHS funds activities that meet its cost-effectiveness standards. This means that, on the face of things, since the Royal Marsden Cancer Charity’s activities are not funded by the NHS, these activities likely do not meet the NHS’s cost-effectiveness standards. The National Institute for Health and Care Excellence (NICE), which sets NHS cost-effectiveness standards, only considers interventions that cost less than £30,000 per [quality-adjusted life year](https://www.google.com/url?q\u003dhttps://www.nice.org.uk/glossary?letter%3Dq\u0026sa\u003dD\u0026source\u003ddocs\u0026ust\u003d1637565043658000\u0026usg\u003dAOvVaw1mBJdAyIrD1lujg7DwYXwC) (QALY) gained, that is, £30,000 to gain the equivalent of one year in perfect health for an individual. The Charity does fund certain activities, such as the improvement of patient environments, whose benefits will not be captured by QALYs gained. Excluding such cases, we therefore have reason to assume that the Charity’s activities cost more than £30,000 per QALY gained, which is far worse than SoGive’s Gold Standard.\n\nIt’s possible that a specific area of funding is highly cost-effective, despite the on average likely poor cost-effectiveness of the Charity. We can consider the benefits of the new CyberKnife machine. Since 2011 an older model of the CyberKnife at the Royal Marsden Cancer Centre has treated 3,000 patients. It seems fair to assume that the new machine will treat roughly the same number of people, which gives us an average cost of £466 per patient treated, not including the cost of staffing the machine. In order to meet the Gold Standard then, each patient would need to experience a gain in well-being equivalent to over two years of severe depression averted. In their annual impact report, one patient states \"my treatment sessions were only about 20 minutes long rather than an hour,\" but we at SoGive have not undertaken an in-depth investigation of Cyberknife’s long term effect on outcomes in comparison to other treatments, and since the Royal Marsden Cancer Centre has not stated the estimated benefit in their public reports, for the time-being it is difficult to estimate the overall impact to a patients’ well-being.\n\nWe can also consider the benefit of the Oak Cancer Centre. The annual report states that it will provide a space to house over 400 researchers under a single roof, but these are researchers already employed within the Royal Marsden Cancer Centre; they are just shifting their offices. The Oak Cancer Centre will also house a rapid diagnostic centre, boosting Royal Marsden’s capacity for early diagnosis, but we could not find a statement of how many more patients this rapid diagnostic centre will treat.\n\nWe do have a better estimate of the impact of cancer research. Earlier analysis by SoGive on [Cancer Research UK](https://app.sogive.org/#charity?charityId\u003dcancer-research-uk) estimated the cost per QALY gained at £1,600. This number, which is based on total UK spending on cancer research and the resulting effect on disease burden, cannot account for specific research projects at the Royal Marsden which may be particularly cost-effective. Still, taking £1,600 per QALY gained as a starting point, cancer research seriously underperforms SoGive’s Gold Standard, if we assume that one year of severe depression averted is comparable to one QALY gained. \n\nAbsent further information, the Charity does not appear to be cost-effective, compared to the SoGive Gold Standard. We remain open to evidence showing that we have underestimated the cost-effectiveness of its activities. Such evidence could touch on:\n\n- The impact on well-being of treatment with improved equipment. \n- The number of additional patients that will receive treatment, or improved treatment, due to the opening of the Oak Cancer Centre.\n-The possible impact of the specific research projects funded by the Charity.\n\nIn each case, we would need to see a cost-effectiveness that vastly outperforms the Centre’s average, which, given the nature of NHS charities noted above, is unlikely. \n\nFor more information on how we define our Gold, Silver, and Bronze rankings, click [here](https://thinkingaboutcharity.blogspot.com/2021/04/sogive-assigns-ratings-to-charities-or.html)\n\n**Conclusion**\n\nBased on the above, we rate the Royal Marsden Cancer Charity as Not Recommended (tentative) under the SoGive methodology. \n",
  "whyTags": "Cancer",
  "UNSDG": "3",
  "ready": false,
  "modified": true,
  "logo": "https://www.professionaljeweller.com/wp-content/uploads/2015/03/royal%20marsdens.jpg",
  "@id": "the-royal-marsden-cancer-charity",
  "summaryDescription": "The charity raises money to support The Royal Marsden, a world-leading cancer centre.  ",
  "uptodatedraft": "probably",
  "images": "data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wCEAAkGBxMTEhUSEhMWFRUXGBcXGBUVFxUYFxgXGBcXFxcXFRUYHSggGBolHRcVITEhJykrLi4uFx8zODMtNygtLisBCgoKDg0OGxAQGy0lICUtLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLf/AABEIAIEBhQMBEQACEQEDEQH/xAAcAAACAwEBAQEAAAAAAAAAAAAEBQIDBgEHAAj/xABIEAABAwIEAggCBgcGAwkAAAABAgMRAAQFEiExQVEGEyJhcYGRoTKxFCNCUsHRBzNicoKy8DRDg5LC4VNz0hUkJTVEVGOj4v/EABsBAAIDAQEBAAAAAAAAAAAAAAMEAQIFAAYH/8QAOBEAAgIBBAAEBAQEBQQDAAAAAAECAxEEEiExBRMyQSJRYXEUgZGhIzNCsQYkUtHwNEPB4RVT8f/aAAwDAQACEQMRAD8A2+IOS0QKFp3/ABEhm9Py2ZsCt1GGyWWpJR8RUEkSK44h41LRxp7SwQkAZQTxJn0HKvm3iP8AiLVSvaqltinj25N+nRVxhmXIvxex6vtpEp4j7p4eRr03gfiv46rE+JLj6MS1Wn8t7o9CtNulw8jW5v2Ciq39IuvMMShqSe1zrO1d8nwmaOkojDl9mXcuFZgO+s2Nkovdk1Hc5La0PLp9eQJO1bOlcJ/EuzD1inHh9EbBUK286rrqo2QxknQ2OMuQ913snWsOGlmrEa0ro7TP3KgN69I7I1wWTFq0075topaIO9B/FJ9BZaJxeGV9ILxQQhKRO1Cm453NhYwfpRdgeaFZuMR70pO5N4GFRKPJTaZvpAGsTy76piLXZK3ZKukKvrvKma18INT22clOFavNj9tPzFTHjI5qpR8tNHuAGg8KVs7FIvg7NVyWPp7qjJx8DXZOFGJDtE91DSzLILb8eRVb2j6xmJEcBTipbWQ+m1CjY8hAsLkbRFT+G9wd+q3TbRQxZPhZJTTdkc1qKEq7Pj3MaWiHc3aTpWXfppuGByN8WxiITqogH5D86BTDyoYCP4ujNYviXWktonKk5fEnifc+XfXSnkJCOBe62A2lIAOgnmTtPqZoYQUKtYII4AqJ+Xv/AFpXHEHLQElIGyQZ46qj1yhXqK5EgS2lCR8uZgR5T7CpTIwMMMcKUhXJXoJkR7etS2dgcvKFwg5IS6n3A4HvoM4xnxIspyisIHuA6pCQrTafKqaaqFU8oBKrLyN7a3kJnWIpuSWMkL5DpA0pMMQcVAmuzgtFZeBXeOhQ0q8ZZiyZwcWiEaV55PNv5jf9Iusk9tVens9KM+HbGStNaFguVJWDqKlxwcmU2t1nURG1WlXtWSIvkuuHssChhYhqVg50d1Pwt22oB5W6tmbfcCTB8K3J6rbgzdL4b57eGFtujJBGtTC5zYS7QKuL5IoTNHsntjkx3wXfRAeNJw1yk8YIi0+AfqUwZOtO7m8F1FY5HOEXalJM7pAEjjMwfERXz3/EXhtWlujfDqUuYvrPb/Jm/pJytqSl+oQwnSOHfqeMyeJ196zJeIXWNqC+JtPj5LhL7IbVMYLAgxfsr7Ole/8AD4TsWZiGr1EaY7Yrkgq6zNZTJIqdfVt5BaS/dHDEL+C3Lq0rbbISDudPasfzEN7uTXt2BUgAp1G9ErnNLMS81Gawyt1gIB0oXm2ysW4VnBQXBnXVkk16iuC2rgypzlnsGcazR40PU17oMa0N7rsRorfCTlBgV55VWLo25WxfZ85hQO6QaiULOmQpw9iP/ZsbCqOqaLeZFlIw/tAAa1T408Fvhxkm90bzGSJo+bo9Av4bDMK6KoC0qI1SQfSj1b32B1Eo7cG5AokuxaPpJBM1OCcnYqDskFCoaJTE2J/a8KpFE4wF4OB1Sa0oJ7UI5w2GG4SDEiauVci1CRvXZOOPGBQLpOMQtUcyMzjN8BuYTPDUngKypM0YxFBWhIzJIlZnz1n+YjyobCY5Aru6gQOOn+/dUEpFSBIPlqe6oyW2k1uQSY1PsP61qqkTtA31hUjbU6+M6mpyQ4laVBKY3E/MbVfJGAa2vi2vMk7a+I2P51Vog2jFwlaQobH50LGJFlFtBjA1puXpF16g8mkwpUuDpXYJTwL75AAEVdLEGc25SRXGledq5uX3HX6QHD09pXjXqbOkZ0PcYOtSCKEuC5Vb2oQIFWm8vJyWETQ0AdBXYcjspHz1mXII4TUOLReElgjZOBS185NE7mXjxATXSNTzk16C2ClSsdmNodU6tQ03xki3bqWQdfDhU6eOyClJhtfNzt21+4xFmpICqK9RCa2mdPR2xTyjlwvTSeWoI+dIaalO5/QS2NNNgS62W1FclknJ4Q4wEwhwnTVI1011EepivBf4ttjZOuMee3+yPQ6GEoVpS+oztToTyrP8CWLp/Yc1HsB4Xg4fcU44OxMAc693Cfl1pIxLI77G2aNGEspEBAHlQLPj9QaD29E/oqQIEAUq9NALvfuVKaCdhVtiguCVLInxpCerUaiFe6SOseIvJg1VvJYSMV8s42O0PGh3cQYWn1o31oeyKy49GtLsrukRJFVmzoij6bJidZofmIlRZfbn60E99KNp2oaXFY8YczqgDbjTae5ijko9hsBMDjROkAy5vJa66EiTQZPAaKAjiJ5xQXYwiggR29VwVFDc2WUUXWeJHZRq0bPmQ4ohi3wlXAiixZR9CHq3ktFSHSO6mHbKKF1UmzyrpFiT6Xg71y8wOhCiAPLaurslJlr6IQ6PTeiWNXb9ulzMk6cj+dEVzzgB5WVkctYq6psBUZyogRMADjrSuqtbwhrS14TYaixTlBX2j30tt45G/fgQY9aZlpyiABoBQp9hYRARhqt1VXkKkkRcbjSqsskDOVQnAOqoKtC66XHz+dFjyCYM0RPt/Xt6VcobPow5LeU7j+vyqmPiObaQ+ZHapifoF49hLqTwpVNe4Yj1Ws1bJAJfiSBVlFuDSOzhoipkgbVh06K6NyckNytjtAsOTqa9DZ7CUBjlqmC5wiqtcnFjaBT9SWBeYTaoiaFauS8HhGKwrFUC8VblUO9pWUgjQcAToTGsDhVHXJfGMV2wb2e4ViB7ahW7p7d1aPO6qGy5h1ldpQiTx4/14ik25WXOqTwvY1YSjCqM1yN0hK0CDS7W18PobzntdmPuMScN87aqSClLaVtBIhStBMkmCZ04bU7pZ7HKXz5MjU17pqHWOP1GFwyEJDpUklICwjieXoYPlQNdrfMqls6+f3G9Bof40YSfLBnceaDgYcEKJDwCQY+riJj9uD5VlWaNysVnfGP1NiekTsUId8s0lvdhDSlDh1R1H2SoTp3pkUh4WlXZba/f/cU1EZNqJNPStlFzcWpSpIt2w4pwQUkKDZAABmfrBw4V6TzcLL6M+MM8LsaO35UhK29QoBQnQkEAjQ91K3auMJJZ7D1VLL3EbB9a1rzaZSBHikHXzmiQk5PHy7JtUYrCC7lEiiyQCLMj0pu8o6scab0dWXuF9XZhYMsa0jNOsjtJ8RQb/wCWxjT82I0NwLgEFsiORrITeDWkuQm0U6pJDseVUnllooTXOHOh0KTqmdaDhhE0NrZP1gnlQEv4qQX+gdm7hOVMZudPqSSwhCVW55LbaTEmTUN8cl0kgDELk5jrpSNk+Q0YlOYAVVMki4cycyRNVciyg2CfSI2867J2MBvXlTS0kyIkUWqXOAdi4AMXug3ZqM8KblFtCyljk8WxhalgKmatVHaTdPckzTfo/wClH0ZJacEpOoPLuq7Ti8gY46Z6Pgl4HQhY2Klfj+NK3r4ot/Ua0/paHtw5pQ5MaggFRoXYTADdnSqMuhc2wVE1Uu3gpuGDwGnOowdkAdQRvVWSL75mRUxeAU0JA4QdaP2BNj0QvJVl5j8JqmMM58o2DJ7VHs9ACPYZNKYDHDVkQwZSZWKb0y5BWhV18J8KbwgeWI8NGpPfSd7+ILV0MKEEORrVfckuTTsGLyDra3kSONTOpyeUR5iR49jtu9cRcoGS5ZOdJAImNSO/jpx1HGqxs2y2y6YSVe6CnDtBKelLTzQenKtWikQTlVsdfuzt3UzVdGiLi/yE56Sepl5iaL+hl4p1L6XNQlyR4Hsq90g+dZPiVko3Qsi+BvRV7YOEjR4el8J6zIrqVGEnQkyco7I7W/dWpSq3S3P7/crbdKNiUeRN0neRaYlZ3BWkjVDoSRmShQjtpGo+Mkc4q1V1coRcMr/YXu3eY5SFTxcbvbhh1ZVICmlK+00pSSkCNNuXFKqV1CXlbYLjKNPw2LeqU5dpMpv31JvXXUGFNspCTAMFS1qOhEbCjNJpL6j2rUtts49xgl+4yxm7W5hofLhzqU2FEaZo0O3eT3UpVTGFjS+pi2WN0pizA7zOu/cJ1U00PE5Gp90Gusfl1Rj9/wC4xplvtb+39jfMXXVMNqcVqlAJJj7I0gbHQbV5/bK7Wtv+l/2DywoPBb0Yu1oeuy8oKUpTSpGgIIV8KZMeHdXrXdHYpe5m1USc5RfQ/RiAJAkSZgTrA4xQPxC3JDEqNpkOlGrpVII2EeA0PnNbGhlmLRk6yOJJiNVOiRK0HbT4igaj+WxnS/zUNr64KVQFEaUnXOChyh2cZufDC7Z1XVFRMmlbpJvgPBNIX2d645srY670ElSyMmlQrU8KT3JWcjiWYCl21eLhUFaTRfMiUdbxg2duohsczpRbJYgAiss4u1TlMnzpPaHMlibjrx6tmQjZTnDwTzq0cLs5xZNVq4kJ6tSjlganelprMsocqniOGVYpa5Hg4FKBI7SZkHvjnV4TeNrBWRT5QdhlyFIWNRoaNW8SFrVwIen2IBFsGx8StK0It5wIyXB5tkSlEEzRE8sp0gZh/tVcqnyewdBbhJtWoOqVqChykgj2pTU9R/MZ03cvyNqtOkmgtDaYsuLhIMSKC2G7Fl3dCqBEkJbvHAgEJ3okKnLopOaXZRbXtw5rkOXmrQep096Y/BWfIX/FV/Mjd4nl+NJgbkAqHqmah6C19Y/VHLWVrv8AswE4ywROfQ9yvTaq/wDx9/8Ap/ct+LqfuLMQQFErSpKR+3nB8hlM13kShxIo7FLmIz6LvZXEuEylM6AKHCI1FBucY9BaoOa5N5geKJfzKSnLlIBHjMfI1CscotMm2jymvqOSaEDIzUo4rbPbFOaYFaX4iewfCmZlIifDBpSd3qC19BwoRcjVfcki4TR3Z8IPZlmgwkfViacobcRa3hmAw3pIwojrAJ5xQuH2GWU+DyvGmupunAICFKPhBOivzq0F5lf1QS9ui/d7Sw/1Rt+hbyAFoKSFrVue9AUBPCddOMGkfEK92m3e6w/0Ji3G3BDFOl74621UrLkUnqlJ7OUJ4EjfMkg+M1p6Gv8AEVQaeOAWo2w+LHuZy+SXEwoDOoD6xQ7RcABSVLO42HKKNVDEXXJcr918wtkFZVGUfdfuP+kqf+6WV4kHO0AIUSVFv7qyd4UFeSjWJptXOzUzon0uvuXjFQatr9sZArHK/wDSXg4lKezGaZVDQhI75zCtH3Q/q9VFUzaWd/C/JIKecnByPuutj/7B+CqGl8Zht506/IWdCrXOp9sfbUATyEnMfIT6Uv4jYq61J+2R3RcKTQ8/SegqaQY7KDm7p0HsmPWkvAksTk+Wymra9C91kT9Cr1SbW5UlRC2y3BB1hS4n51u7U7Ip9Cym1p5td8HqGErC7lhZ4WQcJ7yRJ9jS7rS1SXyTLK2TpyZfCrT/AMNaejVxbjh8FLIHsBWvppfxGhHWL4EylxhQQFkQkkgE8Y3gcR307vW7b7iOxpbjuHiXE+NA1X8tjGkX8RDa+w9ZVmA4Vmp4RotchLduoMFMa8qFMuuhdg9ioCVAjWhpHRDbn4qzL/UaNXpIN0NdhGObO9zrDI3ifStTG+G0zpPbIWYveqKylzsNpMZfvnmTy7qVk2sobhGO3KHdqkdWNBrrVF0VfLOIZA2qFFE5wLnsOJJJMzVFHBZzyTw+xCFSOO4q0G08g54aEPTjop1sOBcZdY4a1pb9q3CXk7meXYzh3VmM00Sqzeil1Oz3FQQBxo4tg2/6O7uC4kzlXATAJ7SZJ9j5caFZRKxZXS9/YPVYoPk9G6R4kUpgnJA1k7eMae9AlCtPDbf2GoOxrMUkvqec3PSBoKyh10q4HL2PTejKurHT/b/YG77U8bl+/wDuC3fSZacycucjv4cSIG1Eho4SW4vLVTjwfWF8soLgJKiNY3nkOW9DnKUJbY8A4qNkd0uSjFGHVISpKyVHcbRr61VSX9QOyMv6f9i7C7J4RJI5zrNBk4p5XAxVCWOQ7o/hKe0siYWpKZ4ZTBjzmmdfqZJqEeFhMro6ItOTXuxhiFhmiB3Gsl2N9j0oL2F6Xkpc6uCMvoTp8qhxyshYrBu+i1rkQT98lXl9n8atFfBlgtTZvnj5D8mqgTs1xwI67ChRHd5VbmU2b5YJ3VzmSR3Uvp/E1qJqKQSdGxZB8OGlOW+oFX0F0IuRmoJOCoySaPDh2BWpp/QI2+o/NTDp50AYTyF45bLWGzkUVFIB0Phr6VFE1GTNHV6eV2mg1Ftrgn0bDjau2lxK2ygpJ+FSBplP7QG3dU6t7oOMXwynh2klZJ+bF5XTfQR00Shx4qbObOEkxwI0174j0qnhU5V1OMuGnwddpZ55QnaDqEJzKlBUAUbqH7XrWtHXRs+Cft7ictBbTLME8Ps1ODsnK515VlIjKsmAAlySkHYEqG3Gsu/Y74yj9Xn6mro9LJKe9YzgyzBcZKklKspCo7J15cO73o01GWHnkXoU4QnVKLxzjj/n3NC1doOFvtz2+vbIQfiI6xoyE7kAT6Gq/wDcMz8Nb5ONr/Qu/R+rIHlEHMpeUCCDllSiRPgkfxVmeLQdjjGPWM/n7D2hosUHui0Pumlwla0WuhCmnddCM4KPftE+ApjwupVwaXsZlvmO1zkmvlk836PuKSp1sGMzS5HMtjrPX6o+taNjUcS+q/fgos4lFe6/tyek9H8RUGLt5RnqrIpR3J1ges1SUf8ANv7f3LQf+XX3G/Rx4fQGrdxB7KEgD7wiQZpW/wAQlU9tfrfRoS0Skk5Pj3E+L3qnVyrTKMoG0Ad3Ct/Q6eVNS3vMny2ef1VynY9qxFdIjhH65NW1f8svpPWaV3GUpXlO3Oshz5NRLgYC7bjMSINSmuyGWMPNrBywfCp4ZyM/cDtqrHsT3M0YPESLO48aFHsI+hjgrQ+lZv2D8xWtT2Ztodj+HBYJyhWsjmOdVuUdj+Zeicty+R8yeyB3Ukuhh9nCuuOBPpPbCedUzyTjgPboiKMjjvR9d21lQ51SucSPMSKdhXKyItKxQZ4t0z6EXdn9Y9DjZMBxEwDwCgdU/KmYJR4FJtyecmSW3RSmDXdCblAWltzY5gnhqvLExxCkJPmavluqcY98P9Oy1bSmnI9S6SYMh85lqVI1CUxvuJnfwrNl3uNKPWDEX3RltbuYpUTPEx7CrRteMFZUR7GHQroyh165fUmWx9U3yUUgBageInTyNMW2ShBQ9wNcU5OfsKcXwNVq6pSAVNKOoHxI7wOIpeFysW2XYWdPlvdHpn1m82qIKj3BDnzKY96I6m/dfqVU/lF/oN22THYQkHXtOqBjkcqM0+BIoTjXHt5+waKsfUcfc7ZWoZQG5KtyVHcqUSpR021JpW+12Tcg1VXlwUS6KAy4kTYlxZJgRtzIFduwsILlG9w8ZQlPJKR6AUzJYrRnt5m2HhVBJLBXHAL/AMVD1fGnZNfrOPfCfCsbwlf5j8hjUeg7h/w16S71CVa+EJmh5CEag46moJNLY/AK1aeIiFnqPzG06kbgmhuKHIyqXvk1OKGSk80pPqkUivUz1umadKFkxRMZI3ODKXNZ76LFAZvcCP3cQmOIoigLyuecGlujoP3fwpJGu3wxY6NKLHsRm+SpsVeRMPkHWBhQoE+hiD4wW9JVFAafTuh9AMb5FtkGjaWWMr8zznjWN0M/85ZnsZt1M3Di0gwTmHg4mSPmPOnd0ZcGCpqPua3AWlPWLyEGA4202pXJPWEr04nKFaUprb4U2xk+8PAzoYqytxfzNkMSS3BUgmAEiBoEgQBWNVZJWebPv+w/dNJeXHoXP4haqUVFtUnf+prUj4naujOlpYN5Z8zf2qTIbVP9d9TPxOySw0TDTxg8oi7dWqiSUL17/wDel/xb+QTYE/8AaFupAbKFx/XfXfjGvYnYxhheHkDNboXlVvJEeOpotWp39FW1F4YPe2zjajnSRNKznhsfqcZLgpbMGhp8hmuB7gKgXCY1jfzrS01u6WBC+G1D19rMIkjvFGlDdwAjLbyZ7EUFkwEqKfvb0lZBxY5XJSXYN15ImhNl0gBDTql9YlJKU7mojFvlFpzS4ZpsJGc9w3pmiG+QtbLah8VwNNK0s4XAljPYM66lYKHAFJVoQRII5EVXzM8Mt5Z4x+kboWm3WHWR9Ss7fcVy8DU79pRwNF0IwKxFslTqUqUpPaKt9RrB4eVHjZGGJMrHTTs4isjvEbIZAUPrcSNE5ghR8CoAE+c0tbdXnO1fuPU02L4ZSa/QQPWC19lRITx+FOneUgEjuMigrVKPpSX/AD6h3pk18Tb/AOfQ0ablu3ZS2kABKQABwpadrLRq/QzF/iKHFFJMdwIn0oCT7GPh6AbLJ9oa86Mpy+YLCLn3APhqrbYRYRSHapgq2MLRnrAR3GT5VDQOTwW2GF5CFFUxsIj1rqkmyLLOOBvZK1NM3dCkPcOCqXCEwquJAnT26DrnjTsmr+YduPhNZnhC/jh9T/LJWXw16C71CkPSgmhFzlQSdTUHGktPhFa1PpELPUfmi7wm5ZEvMrQOZEjzImKjCfRRTwP3jLbR/wDib/lFZ/U5I9xoXnTx+wE9tRIl7QWiewsDKZzOoASVdpMgcpEzyosX8PIjqZbeT1Lpn0fYZt+sbCkqCkpgqJEHfQzyoVlUYxyifD/EbrbfLm+Of2MEvagxNWUfiKRRWUXDC7TegTYaITeqPWoiR2R+NRV6WeO/xA/48ft/5GNutR4n1rpHm5djbDlkbEjWlbV7lU2uh1iKR1Y8KDZ0j0dHEF9hFaWSMyusUkSJBJ2FEjBtj600nHKKHGmssJOaD8QqXXP2DLRya6CU2iDC8pCBodt67ypAnpZ5wUW+QKOo30mqyqkWWitN/wBGcVa6oJzjs767a0zp/wCHDv7iGo0tqlzEF6V3SXAkIIUAZJGvvQL5qyzMegukqnX6lgQBsjcVXa+h1vA96PMFLis33R71o6SqUJPcJaicZwyjQUyKnFJB3E12Ds46AbrCkLM6juFBnRGTyFhdKJaG0toyJECKIkoRwiMuTyyWGsBDfedavVBQjkpZLcy9yrsqgB80FhYguK2qblhbKvtAx3K4EVZSyVcQTozgASwlK09oCD4invLi4rIrDUTrfwsNxHDuraJQNJ186U1VKUcxHNPq5WT+NmMfuznidjWalk0pSWMBWI2YUM4PaiPEV2MFYyzwZ59AG+9Wzks44BHbhKdCoDu4+m9WUWDZKxuc86EDmdJ8uFTJFE3kINVwTkc4L+rWfAUOa4KN8hyVaV1C5K2dF1id6PcCgHg0AIyc1BwIT26W8QeNOWp9Z25PZNJeDL+Mwmq9BdZjsituz1MXh6UXmhlj6Kgk6kVxxpLb4RWvV6UZ9nqEdv1XVhCkhQywrNqIG8zQ4STQKz1MzN70SacOZDmRBAypSkEBMaRrtFeV1HjEoXSioe792el0eunVTGGMgLvQduP1y/8AIn866PjNj6h+4V+ITl3Ei10CbOgdcn91EVafjVi7gv3KPWyXshnh36P2WlFalKWTsDASOOw3PjSdvj10sJLCE7dR5naHPSmy+ks9UFZO0lUlObadIkc6ff8AiKM44cP3K6Nuize+ezIo6CEn9eIGp7BGg31zGKNp/EpXzca4fuac/EUuXECX0MUDo+k/wH/qq78UxxKD/Ulaz6BVp0RI3e9Ef/qlrPFV/p/cn8fjqIxX0TbKklS1EgRIgSBsIM0vHxecYvbH3MbW0x1U1OXD+heno62niv1T/wBNVXis5cpIRfhdT92FWuEtpO6z5j8qFZ4lbjpHLwupe7CcbQA0I4CPTTWtCFzt08JvvkYjBQe1GKxhAytkjhWjFfAmbvh81jDALdPKobwasoplj4qIyeQDriwYDWiyk2ugLjhhVjI2J176DJ/IiSWeTdYOCm3HZmZNWhW3FYRmaiUVZy8HWrV1aVOJA00AOhnuprRxW5zmuhHxCcpQ2Vvsz+H3N1bvLC0qSFGdRIJ20IprWzi0nB8iHhFdsXKFq49j0Kwuc6RO9Aqs3Lkctr2MKooI+riCtSMxipisvBbOEfXTuUjaOVEk0isVlEluAiRtUSZyWBdcmgsLEGQ7B86qnyS0PrFYKZFaFUt0RC2OJH2IEZCDx0q8kmuSkW08o88xzCRJMSD/AFrWRbS4M2Kb1Ncg7GFJU3Jz6aQFED02oSkxlSwxPeYWn9qORJqysZdvIKmzSn4QBVXJg2y1CctSuSjIuO1Yq2OsIdJaVAnb0PH+udDm+CmOQ8bVFB1hJi6QjVSo7tzTU63LAm9RGHBB7H2xsFH2rlpl7gpa1+yBj0rSP7r3P51byIfIH+LmRb6VtTq1B8T+dRbpa7Y7ZLgha2yLygk9JbdQhSVDwP5zQqNBTRLdWv3LT8RlNYkH2WM2yhAWR+8B8xRZU5eS8NcusDVoBQlBCv3TPtvQpUSGY6iDKFvgHKd6C4tdh00+i9vcVVdks0TI7IrXr9KEJ9nkn6RukSm1NWTI7b0FRG4STkG3MhX+U0tQvhbfSOnWpXKK9w5N1wOoSkAAEjQAAbUiq4rnCPXKhQWIlSrlB3Lnhn/2ooRVzXy/QpceE6KWP4j+VRtz2i6g/dJ/kTRerTs+vyUfxFR5VfvBfoirog/6F+gXbYisqANwQkmCVwYHE6b0J6OiT+KCA2aeKi2q8v6Gtfx21S0UtrSTEd57yYp1V0VQ2VJIw69DqJWZnF4M4m/TA0E9ypHlpp4Vj3eHwazFvJp/hXkaNfOsC1PoTawHN8KTlJ4aByCyEKRBEKHuPzo6nS9PzxNPj6oB8an9AJTMGg+ZuDZyLMfv2Up6srAXGoJ111HtXodGt+kgorrP9wEovdkyOJOpW22BrlmfwrXUsVqL7NHQRaeRdbTNUng3YyW0Ic7xU1SjnkBNvHAKvemJ7ccC25+4Rh80pa0XUl7nrdjZhFujWCECT5Vt11RjUvseUt1M53vj3FhvI06ys6W72Y/8PuiwAK+KFeNC59y/2IM2ikqzNqMfdJ28KlZTyiJTT4kOrS6ChChChTtdqkuexKdbi8rok85lE1E5bVkiKyyoLX9lEk6a6AeNTp7HJ4XZ09q7FmLWdyUzmQf2QSB6wdapa7E/iawWhZHGYoX9HbxwLUhYOSSnXXKobQriD+VD83ZPY3nPuXfxrcN7ijsqhV1nbIoOeSw9wVzUindM/YV1C4yV43dwY5CmJvArETsWqs0rBhQ+E6T67Ac/SlOXL4huOEuCK2AgEJ7SRqSAYH5jvpeyprlDcLcvkRX74Ko4UvjI3kVPJ10FTtIbFl7dhPZGp+XjV0gbYG2STKqiTISNN0fe1ynYgg/h7xQPoS0NLsFAM6cu/wAKLRB5AaieINmdedrQwYwM87oakgFLk1xDKSrWuBs7UgWdBjauICbbEnEGUqNdjJKm0aPD+lytA6Asftb+R3qriM16mSHgx5kI6wE6bo4+RoEqE3wPw1qa5NXguKNXDQcaUFDY8weShwNNVtYOypcoyFqhl+1VeOtNl5H1aVxqnXSJ2PaNLX0xrjJZ90MeHyd90G0IhqFHlSh6/jKQNOtE9guOCl461KLwXABfPZSmDUvrJ07FBLPuStSXCdTAgmPy8ao5YYB2yc0g1aSInSrpph01JPAVbnShy54AzRsLbVKT3CvHX5U5L6sw7FiTDAaTaAlqF0JohotrljJQ866aXRTdFKkpUAEEBSQeFes8Mr/y+M/McpUJR5QvfxBtyBlDXcjb04U5XTOHvkaqhGC4ZdhuHKdOVpSCeRUAT4A0aEHYFnqoVL4g256OXY0DR8iD+NHhorW+ULz8V0uPUAJ6M3M6pPoae/8AjpvpoQfjOnfzNBg3R9xshbqCoaEAfiKWWixNqzotbrVZWvJeWbe3eUsAFKk+kVGo82GFBZRmxlhZlwxZiDK0L0SkpOuYjauhVKUc4CK5EfpHh5UGcWuxhTT6L2LkEwKomQ0FjmN6nrkq+Sa1lYgDUc9BNFebI4QPbsYQHhsaTjqJ1NpA5V55F+J3aQNeFJW2SYWuOBE7iaRAAAlXaO0zuSfDj3VWqcpTQXaOlOBzVs5/3dflXoU93QBxcPUsC+yw94uKKmlJE6KMARz11qsa5Z5REpxxwx/aWgQQSrU8BypqENjyLzluWDhfQSpYAgT2uKo5HgKu5ZKxhgWpJdUVny7hQuwuMCrEsYSjsNgKA1JPEiobzwSuORZi7ICpAiQCOG+sRSPTwPReUZ+6zHQH00qxIodbg1BxJhtSjCQT4cPGocWyG0ux7h9vEayZ4VMaecsHK72Rq0WK3G1JUBlPP4gRsRHEcqYjFoVsxJYZkMaw5bCgFwQdlJ2Pd3HuoohOtxE9w7pUlAcLrikiKTXFH0WipAvskK44rUalFWSQquRKZJ2+LTao1kRrXYyErEFl0ifZKuqdU3micpiYmJ9TU+UmN1NwWD0TDrsi3W1w6yfQf70LXNZS/M2/8PUvM5v2eCYdhtQ5x60h7nptqdiYE2dau+g7XAPcOlIKgMxGw590VZJPsrc3GuUl3gGssMVcDr7g9WmdEoEb6CTrAq07IRWInnoz1FrW59ewVduptlJSgxn3EyYGxCo03pZRdibHY3JyUJvDOFcwaPFJI2VBRWEHMHs1SQCfY/ZxlltCQ44AoAaQo/IV5vUaK6drcYmBqrIwsaZMdKLX/iE/wL/EUB+Gaj/Sv1FY31yeIv8AuB3HTVpIJSy+sATKUJjylQo0fBbJeqcV+YWzdB4cWUW3S26cUki2Sy12ipTqpMR2fh+Ezw1pp+CaaEfim3L2wuBbfNy6wvqcxjo65iZQ8LpDSEylKm2lKnXZSisTHLvNanh9NenrccN/crKcu4M7Z/o5UnRV8Fjvt4Pr1tNTVcuU8BY6q1LD5HFh0EaSQpxSXANwEKT7hVDVOXlyyvsXlrJ4wOF4G4hJNncONqGyHZdaPd2+0nyNNQjx8EmhOU4yf8WKf9ymxv74CHmWieaFqB/ykR71VanUr6gJS0TfCkhwypZErSEdxifYmmar72syWDnVQ+Y5O5o+HfxEVfzpf6DvL4xv/UWXdxeCcluh0f8AOCT7pq0L37wBWUPHEijCsIde7T1q2x4PFavQJA96iWyzuBSt2wec4LnejSWllxDqo4o1V6a0nbpq1yuBpX2dt8Flu+SqMpCSJk93PvpZYbwuhiu1WLg5iD4ShTiXAMo2UN/MbcKJwluixiEZZxJCHoS9dXAeddbUhsqlvPoTwUUzumRvtQLNJNvdFlLLouXWBti9ksogCSeAIpCymxexEZJmbxro9cuNKbQjcQSFJk9w1o+m08ovdJFpTXswbomu6t7hDTqVNqJSDm+FSRvHPSfCtCuDjZlBLbY21/EeiXF3lGdZ8B38KecjN2oW3d8oDKT9Y4CdPspGsVVsskVuOdhKNhAPgB/vr6V30OK74LIDSBqrfuTy8eNQ/kixfhuANpMqGZQ1k8KtGCKykVYxhXWkkKidwfmDw8KBbRueUGqv2rDM87gakpPwk+ND8qQbz4i1vAASS4So/dGg8+PyqVV8ykr/AJDJrCVKASAEJ5AR8qIogdzY0wvAwCCBPef6+VWUOSGzRstBIgeZq/RUCxPCWnkKQuYUIkfZI2UPA1GEdJZWGeQ9IsHuGbhFskSpxYShyDkKTrm8hJI7jvXcJNsTdUt21Dd7oS4B2LgK02cbiT+8k6elKrVJ+wzLQ/Ji04Dcp3bzDm2oKHpor2q8tTVB4k8C09FbjMVkEpgz2fCuIIuVKIZ8gVxyQpx5/ZIq0UMQQssMOdezdUgryxMcJmPkfSplOMexlRcuj1lTSQVNjeSU95J41lym7HuZ7XS1KmqO38wa50ASQQd4+VVQ7Bp8o7ZWBXmJWhsBM9sxMcAOJokVkrdqNjWE3lgb7cCUqSTrVc5DZymmhczjTiE5AkeJ7u6pVaeW2Ys18S2im8YecczrVJiQdo7gKYhbCEcYF7PD9RvyvyHdqlWVIOpjWhNnpa90YJS7wNmW4EBQPHSgtgZSy+ix7oeLhXW/SlNhQA6tLCnDoACStKuP50xTzDB5XxCv/M7pLKDLXoO2n/1Tnh9GcHr2qiVKl3L9v/YWvVV1+mv9/wD0MG+hrehD7gIOig2Ex4hStRVPw0V2/wBidRr5XRw4L9R9Y4eG1aOrVoOQAPDQbnj6VP4aDw8vhiTlJ9pBwH3tR5a+OlH2wxhorjj2LUlP3BV6owk/SDs3RXD5Pp0yp7ImdPPedxrXRkovCXBZrPLLLUkJAKiY4nU1flsrjBieinRIKSp19y5S4HVqCVOuiEpcOU5c0QYkDlFDVSkm5f8AgiyFaa2r/wDTZuPiYJnTiAahTx7l9p1pKVfZEc4/KjKTKMILRHwpFdJzXRHHuRJWDBEctqBOy1cEpRfRnbywvF5+ouFpXJI61tstjXaAAoiOM0KqE5zw/wA2JSplncui/o5ZXeV1N442sggJLaMgA1JMkmSez4d9Hrgm2muAmmbg2xZjmHJzBCnQW1HtDKoHT9ragTqjF8M11fJroboxBMlIICQmBEeAjyqXPDwA2gD90RCQvMR2vThz1rnJNEFbdyoqzFfY3AET+6ZHCPeqOSRZLJXc3xcfG0Jk+GhTI9Yq1cm55OfETlvcKdcIXAS2QT36aECmkC9ge3uesvComUhJE90VCfJ2OBjhb/XPqgQhAknhySP65VddlX8h1oAVJHmdyak7JwO5ewAVLOpj8TXJkNEXU6az7/MVxwGu3B4T6/lUYJJt2Cdzp8/6867BOQhLCEgqOgHE7em1cQdTcBQkbcO+uJIOr8vGqkgjl2kTK0jmCdqjJwE/fhMjRQEaTuCYn1PvVW88M7ooZuErBKZHMHcUhbDa8oZhLciNuqJJ2En0rL8Vy3GKD6d8Ns81cclRPMk+pr00FiKXyPJ2SzJv6n1XKkFGuIZ9MCa4tBGXxF7Ms1eI1Wj2b9CmDhFkp9Se0+skSPsI7CffOfOgzipy+w5W9sc/MU3h7ZPPWs2HR7utLakcurxU78BFSkmTXVH2AiskSTVw6SXQOozUhEkiv6Lxg12UCdVW7djki6gzpp3GoxkmyuU2nFlpd0ipSCqOC+0XBk7VElkHYso9BwHVkKmBJ3omnrckeS8Ss8u34hiqANVADz/KmvwsvoZb1cD4KmClQO86HXTw5xXPTNe5H4pfJl7aBz37j7TU+V9SfOz7MJDB5eulXVUV3yR5snwuChcTBUPAcPasbxTxOeklGKjlPvAeur39yCblObLmT4kgR4zRNHrYaiO5Jr7hXTLbnAQl1vKVZ5AOsbe9aFcoyWULyynhiNfTS3TcqYJRIEFRXJ2mIA03ipU5KWMcfMUhZOdzrS4XuEnFsygG2xqPiU2qP8yyByokVD5DjqfzGVvfORBacPglKU+W1WcvkgexZ5YU2tR+x6muTZLUfmTcBmSfLT8TUShl8lY49iIeAHa080121fMjHJ14SKlrKwTBpMy2MYl1EdbAB2O8+A3rPmpxZpVbZo8y6T4sty7BtllMiOwShJ5TzO9WrxhuQG9cpRBlXd/OUPLkj7yfyqd1YDEwR65vAtCHbhaQoxOf1qfgabSJSluSZqMOf6tK8pUpSkxJMnfXWg12pSwx2yj4Ph9gdeKrUggKIUOX2h938u+mxEc4NcTbB1IlTnYRprAPbOveI8jUxRGeB70evm2ibdWYK0Up0iUTtkJ30111G/m1GiTWUhd3RT5NO6cqZ0iJHEE9xoTTXYVNPoptVZQSrdWpNQuiWWNuA/CPOoOOXDuXjXMlEGyEjOswPwqF82d2Z24xBVy6EJ0bB2HHx7qG5bmW6DLzFEtEISMy9Bpw7hG5qXL2RCA8RQuAp1ZSo/ZTEjxJkT3QarL6lkIXLfMCQtQ8wPcAVQkRXS1pCjnVIjUnNp4d29cVaCsG6RBKwF/CdCrlOxPd3+PlFkNyOhPDHeNXobt3TOsZR4qOX5EnyrOs08rNTXxwGuvVenm88mBQ7W2eXyXlVcWyRKqkgGxB7Kg1HuGrMyQVEBOpJAA5k6D3oj4Q3GOeEfqbA7BNvbssJ2bbQj/KkAn1pdN4yO4SZ5oq2cUhSwkkZo2M+VZ0Ue1VtcZKOSh/D3jGVpZ0H2TV4phIX1R7kjicHuYEW7h8jUuLyS9Xp88zRJGCXfC2X6VOxkPWaX3sRJWB33/tljyH513lv5FVrdH/APYgdzo/ecbdz0/KrKDQWOv0vtYiBwa5G7Dg/gVUYZP4yh9TX6ljNivZTax+8lQHvQpZXOCs7631JfqbPBpDQgKBk6pP4RSs9ZTW8N4f7nn9XHda+U0OmUhaYcIB7won02HlTlPiFc+HavsZdlEc8RI2Vo3JzACDpKzr35UgfOnKdXF53SX6gbdMljCLXL5KVlASuOBSkhHmoak+dRZ4hVD5fqTHS8ZQPd4o4PhQrwkfnr/mpV+Iqaai1+QaOmFL+JXK0HMwpagRCGyjNHHMSvQbceJq9UvNWLGmiZVxj12BW+FPvqKlpFuDwzqWqdhIiBw4+dW/DUx4hwv2G6dbOuO2SyiX0O7YBzZXmxqMva1HNCpPzoTrlD0sYU9PfxLhl1n0pZCsi20oVA1CYEneCNRw9aPXqWvUKT8PjCb2SHQxIKALZkHkQsieMk/MGm42RkuGCVMllMOt7lX2TKf3SSO5SSoQfCr5F5wLS8pWucAcw2R7kmu3cgtk18jpcIMFw68o/KrNxOUbPkglGUD41HxURVG17EYl7g15olRGY6HZUnb7MnehuWU8olPk8vxrE1WhVmR1qCSuDqoTuQDwpRR3jsrFXyhlh3Rhi8y3dyVIGVJQ0hWWARoVqHGDsPemYVxjHkWttnPoVjoy2u5yMvltqdSpUqgHZBPGoXlyl0Dbkl2HdIujmGpSEjMV/wDEKlFRPnp7VeUoRWERH4nyzMYO+UuqaJnKYCtpHOkLoLtGjRc84Y6xHo8XFJWyQMxGccpOq0/OKmm72ZW+nndEdXykMhJI2GVtExomJUTw234mtbTUOx59kZl13lrHuEYY6HmgyAhLqUAtgyCUgxlVpMAEfPXU0zKflSznvtfUXUfMjj5F+DXXVtn6R9UjrF5Er7K1gQCopJ1lQURGgEaxrSbTskNRahEa22Itu9lQKCSAme0FTtBGx7iPM0SdDiVjamMHFobT30BtIKkL7YZlZlbb91ULsznSrGCs9W2dBvHHuqk5ZZMeEUsXH0a3zf3jnw8wDx7q5cI4bYPh5aR1z2rpEgK+zPP9r5bVZLCI7A32+sJWvtHhrp5ChNe5dC9ggkjSPOfc1BxnMR+JWxjfvER+dcVZmFHItSOR08OFF7QL3DsZxAqbZE7kg6/cAH+oGrxfGBXWegCac1omDHUghblQEbOpVUEoV4y9wqUNVIJ6AWHX4hboIkBec+CO184ql7xDHzNHTRzPPyWT9KVyQRrIJZfD50Gvoat9f5DBFGQoydEKomKsQz6pOO1xByqs5+xS/Q5BoALvw1heK+lh12BjevGv+YvuHfpLX69npvQisD5z7HhWD45/MX2Ij7gdz8RqvhHuMV+k+svgr19P8kBb6z6w3PiarDsmXQW7tXWekHDsQ9Iv7O7+4r5UhR6x1GZ6G/gn/VTj9aCv0Hpb26fCtT2Rkx7ZXYfh+FXJs7CXdv4fxrvYCuzv2R4fgKH7Msuyi++D1/GrW/yy1fZ5l0s/Ok6+wtnY6w/+yI/cT/KKPPoSsEln/aE/xfymlYeoFH0ksW+Kun2TX6jM2f6/zPyrrfSO1eo9Awb4aTRosWY5+u/w0/jXrtB/0q+55XX/APUoE6J/2lHgr+RdIz6Y5V7fc7jf67/Db/lFd/Sif6mPMB3t/wDmI+Zpj/tsFL+Yae++Gs2Q4uzjP6k+Brl0SeZXnxK8aCixocV/tVr/AIP81EXsVfRo8Z41afRMRd/d+VC9iwntfiVVEcIr/wDWq8B8zUkGVxb9cfAUWPQCXYLiH91/F/pq8O2K630FjNEMVBKtqgKSTUF0JMU+KpiOVGp/Q/8A+Yf4avmKDqeo/c09J/V9v/J76KJE5n//2Q\u003d\u003d",
  "confidence": "medium",
  "impact": "low",
  "suggest": [
    "THE ROYAL MARSDEN CANCER CHARITY",
    "The Royal Marsden Cancer Charity",
    "the-royal-marsden-cancer-charity"
  ],
  "url": "https://www.royalmarsden.org/",
  "howTags": "Research, Direct work",
  "simpleImpact": {
    "number": 1.0,
    "@type": "Output",
    "name": "No Outputs! for project Project[Oak Cancer Centre 2021.0]"
  },
  "meta": {
    "confidence": {
      "notes": ""
    },
    "impact": {
      "notes": ""
    },
    "recommendation": {
      "notes": ""
    }
  },
  "name": "THE ROYAL MARSDEN CANCER CHARITY",
  "lastModified": "2020-09-18T15:47:15Z",
  "category": "health",
  "subcategory": "Treatment and Prevention",
  "englandWalesCharityRegNum": "1095197",
  "whereTags": "London, United Kingdom",
  "uk_giftaid": true,
  "status": "MODIFIED"
}